Design Therapeutics Ownership | Who Owns Design Therapeutics?


OverviewForecastFinancialsChart

Design Therapeutics Ownership Summary


Design Therapeutics is owned by 1.63% institutional investors, 36.09% insiders, and 62.27% retail investors. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 12.90% of DSGN shares. Fidelity Select Biotechnology is the top mutual fund, with 1.48% of its assets in Design Therapeutics shares.

DSGN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockDesign Therapeutics1.63%36.09%62.27%
SectorHealthcare Stocks 279.19%10.62%-189.81%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Price t rowe associates inc /md/7.29M12.90%$705.90M
Durable capital partners lp3.46M6.12%$334.67M
Vanguard group3.19M5.65%$309.29M
Conestoga capital advisors3.12M5.52%$301.76M
Jarislowsky, fraser2.89M5.12%$279.97M
Fiera capital2.56M4.53%$248.02M
Primecap management co/ca/2.24M3.96%$216.78M
Mackenzie financial2.13M3.78%$206.81M
Connor, clark & lunn investment management2.05M3.63%$198.72M
Frazier life sciences management1.95M3.44%$7.54M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Zeno equity partners llp266.28K6.86%$25.79M
Conestoga capital advisors3.12M4.52%$301.76M
Herald investment management230.00K3.65%$22.24M
Summit creek advisors258.25K3.43%$25.01M
Durable capital partners lp3.46M2.75%$334.67M
Geneva capital management1.46M2.57%$141.16M
Triasima portfolio management253.85K2.25%$24.58M
Pembroke management125.98K2.24%$16.70M
Grandeur peak global advisors230.82K1.79%$22.37M
Jarislowsky, fraser2.89M1.70%$279.97M

Top Buyers

HolderShares% AssetsChange
Congress asset management co /ma1.22M0.85%1.22M
Norges bank1.12M0.02%1.12M
Kynam capital management, lp904.02K0.29%904.02K
Ubs asset management americas690.48K0.02%690.48K
Blackrock566.21K0.00%213.67K

Top Sellers

HolderShares% AssetsChange
Arrowstreet capital, limited partnership611.83K0.05%-633.32K
Jarislowsky, fraser2.89M1.70%-438.99K
Ecor1 capital---426.68K
T. rowe price investment management1.70M0.10%-379.50K
Price t rowe associates inc /md/7.29M0.08%-313.25K

New Positions

HolderShares% AssetsChangeValue
Congress asset management co /ma1.22M0.85%1.22M$118.30M
Norges bank1.12M0.02%1.12M$108.88M
Kynam capital management, lp904.02K0.29%904.02K$3.49M
Ubs asset management americas690.48K0.02%690.48K$66.87M
William blair investment management212.81K0.05%212.81K$20.61M

Sold Out

HolderChange
Farther finance advisors-8.00
Fairman group-8.00
Financial gravity asset management-11.00
Massmutual trust co fsb/adv-12.00
Harbour investments-12.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20252-99.51%927,399-98.96%10.01%2-99.00%--100.00%
Dec 31, 20244146.43%88,660,48610.86%1560.78%19813.14%145-2.03%
Sep 30, 20243383.68%65,782,856-1.17%1160.84%160-15.34%12636.96%
Jun 30, 20243236.60%66,550,5312.13%117869551.63%1868.77%92-6.12%
Mar 31, 20243035.57%65,164,649-1.21%-0.00%1714.91%987.69%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Select Biotechnology839.13K1.48%-
Vanguard US Total Market Shares ETF800.90K1.41%-
Vanguard Total Stock Mkt Idx Inv800.90K1.41%-
iShares Russell 2000 ETF795.88K1.40%390.00
Vanguard Institutional Extnd Mkt Idx Tr426.27K0.75%26.76K
Fidelity Small Cap Index312.64K0.55%-
iShares Russell 2000 Value ETF276.69K0.49%-
State St Russell Sm/Mid Cp® Indx NL Cl C269.86K0.48%-
State St Russell Sm/Mid Cp® Indx SL Cl I269.86K0.48%-
iShares Biotechnology ETF190.13K0.33%-892.00

Recent Insider Transactions


DateNameRoleActivityValue
Dec 18, 2024Prasad Deepa-Sell$23.86K
Aug 09, 2024William Arsani-Sell$3.46M
Mar 22, 2024Schmid John P.-Buy$33.13K
Mar 25, 2024Schmid John P.-Buy$66.61K
Mar 25, 2024Berger Heather A.-Buy$4.87K

Insider Transactions Trends


DateBuySell
2025 Q2--
2025 Q1--
2024 Q4-1
2024 Q3-1
2024 Q2--

DSGN Ownership FAQ


Who Owns Design Therapeutics?

Design Therapeutics shareholders are primarily institutional investors at 1.63%, followed by 36.09% insiders and 62.28% retail investors. The average institutional ownership in Design Therapeutics's industry, Biotech Stocks , is 63.96%, which Design Therapeutics falls below.

Who owns the most shares of Design Therapeutics?

Design Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (7.29M shares, 12.90%), Durable capital partners lp (3.46M shares, 6.12%), and Vanguard group (3.19M shares, 5.65%). Together, they hold 24.68% of Design Therapeutics’s total shares outstanding.

Does Blackrock own Design Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Design Therapeutics.

Who is Design Therapeutics’s biggest shareholder by percentage of total assets invested?

Zeno equity partners llp is Design Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.86% of its assets in 266.28K Design Therapeutics shares, valued at 25.79M$.

Who is the top mutual fund holder of Design Therapeutics shares?

Fidelity Select Biotechnology is the top mutual fund holder of Design Therapeutics shares, with 1.48% of its total shares outstanding invested in 839.13K Design Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools